MEI Pharma, Inc. (NASDAQ:MEIP – Get Free Report) was the recipient of a significant decrease in short interest during the month of July. As of July 15th, there was short interest totalling 6,600 shares, a decrease of 62.7% from the June 30th total of 17,700 shares. Based on an average daily volume of 97,300 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the company’s shares are short sold.
Hedge Funds Weigh In On MEI Pharma
A hedge fund recently bought a new stake in MEI Pharma stock. Cable Car Capital LLC purchased a new position in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 611,440 shares of the company’s stock, valued at approximately $3,546,000. MEI Pharma makes up about 3.9% of Cable Car Capital LLC’s portfolio, making the stock its 10th biggest holding. Cable Car Capital LLC owned approximately 9.18% of MEI Pharma at the end of the most recent reporting period. Institutional investors and hedge funds own 52.38% of the company’s stock.
MEI Pharma Stock Performance
MEIP stock traded up $0.15 during trading on Thursday, reaching $3.46. The company had a trading volume of 50,467 shares, compared to its average volume of 57,356. The firm has a 50-day simple moving average of $2.95 and a 200-day simple moving average of $3.66. The company has a market cap of $23.04 million, a price-to-earnings ratio of 0.88 and a beta of 0.86. MEI Pharma has a twelve month low of $2.73 and a twelve month high of $7.87.
Analyst Ratings Changes
Several research analysts have issued reports on MEIP shares. Stifel Nicolaus reiterated a “hold” rating and set a $7.00 target price on shares of MEI Pharma in a report on Friday, April 12th. Laidlaw cut shares of MEI Pharma from a “buy” rating to a “hold” rating in a report on Tuesday. Brookline Capital Management cut shares of MEI Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, StockNews.com started coverage on shares of MEI Pharma in a report on Thursday, July 18th. They set a “buy” rating on the stock. Three equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, MEI Pharma currently has a consensus rating of “Hold” and an average price target of $7.00.
Read Our Latest Stock Report on MEI Pharma
About MEI Pharma
MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.
See Also
- Five stocks we like better than MEI Pharma
- What is the Dogs of the Dow Strategy? Overview and Examples
- Viking Therapeutics: Pharma Stock Soars on Positive Earnings
- What is the Nikkei 225 index?
- Top 3 Small Cap Stocks Emerging as Rotation Winners
- How to Effectively Use the MarketBeat Ratings Screener
- Bargain Alert: 3 Stocks Worth Watching While The Market Cools
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.